No Solid Evidence for Pre-Participation Screens in Athletes

Share this content:
No Solid Evidence for Pre-Participation Screens in Athletes
No Solid Evidence for Pre-Participation Screens in Athletes

THURSDAY, April 21, 2016 (HealthDay News) -- There is no solid evidence for the effectiveness of pre-participation screening in reducing the number of sudden cardiac deaths among young athletes, according to an analysis published online April 20 in The BMJ.

Hans Van Brabandt, M.D., Ph.D., from the Belgian Health Care Knowledge Center in Brussels, and colleagues discussed the potential harms and benefits of pre-participation screening for reducing the number of sudden cardiac deaths in young athletes.

The researchers found that very few people at risk for sudden cardiac death were identified with the most basic type of screening, comprising medical history in combination with a physical examination, as recommended by the American Heart Association. Increasing diagnostic yield by including a resting electrocardiogram has a sensitivity of 0.75. Screening may also lead to false positives, with specificity ranging from 0.70 to 0.95 in a small case series. To examine whether screening can reduce the number of sudden cardiac deaths in young athletes requires a randomized controlled study, although no such study exists. A population-based study from Italy suggested reduced incidence of sudden cardiac death with screening, although the data need to be fully analyzed to identify causality. Screening is also associated with certain risks, including the need for additional testing, which may cause anxiety and psychological harm.

"As long as those at high risk of sudden death cannot reliably be identified and appropriately managed, young athletes should not be submitted to pre-participation screening," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »